{"member_organisations": "", "identification_number": "294466410821-65", "fields_of_interest": "Humanitarian aid and civil protection, Trade, Competition, International co-operation and development, Business and Industry, Environment, Taxation, Single market, Regional Policy, Research and innovation, Public Health, Climate Action", "head_office_address": "Ikaroslaan, 41", "full_time_equivalent_fte": "1", "person_with_legal_responsibility": "Beernaert Koen", "inter_groups": "", "financial_year_start_date": "01/04/2016", "grants": "", "head_office_country": "Belgium", "eu_initiatives": "Medical Device Regulation \nREACH \nBlood Directives \nCross Border Directive \nHTA", "organisation_name": "Terumo BCT", "belgium_office_post_code": "", "number_of_persons_involved": "2", "procurement": "", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "belgium_office_address": "", "subsection": "Companies & groups", "belgium_office_phone": "", "number_of_ep_accredited_persons": "", "overall_budget_turnover_as_a_range": "", "belgium_office_city": "", "persons_accredited_for_access_to_european_parliament_premises": "", "estimate_of_costs_absolute_amount": "", "registration_date": "14/03/2013", "website_address": "http://www.terumobct.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Zaventem", "membership": "MedTech Europe (EucoMed) www.medtecheurope.org/ \n \nMedPharmPlast www.medpharmplasteurope.org/", "head_office_post_code": "1930", "goals__remit": "Terumo BCT, a global leader in blood component and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.      \n \n  \n \nAs we strive to make even safer, higher-quality transfusions available to more people, we can unlock the potential of blood and cell therapies. We can help our customers bring even more treatment options to patients through advanced blood therapies. We can support researchers in developing cellular therapies that may fundamentally improve health care. Terumo BCT is guided by our customers' needs, aspirations and ongoing drive to improve efficiency and patient outcomes. \n \n  \n \nTerumo BCT \n \nUnlocking the Potential of Blood", "industry_forums": "", "head_office_phone": "(+32)2 715 05 90", "level_of_interest": "global", "relevant_communication": "", "financial_year_end_date": "01/03/2017", "estimate_of_costs_as_a_range": "300000-399999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "naamloze vennootschap", "person_in_charge_of_eu_relations": "Nigel Talboys", "customers": "", "belgium_office_post_box": "", "position": "Director Public Policy & Government Affairs"}